The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ECCO 2017 | Next generation sequencing in lung cancer
Keith Kerr, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, Scotland, discusses next generation sequencing in lung cancer at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands.Current molecular testing in lung cancer is focusses on EGFR mutations, however, there will soon be a need for testing for ROS1 mutation. There is an increasing number of tests that are required to be carried out on a small sample of tissue, which presents a challenge. This can be resolved by using next generation sequencing. Despite it currently not being cost effective, it is getting increasingly cheaper, and the more tests that need to be done, the more cost effective it becomes. Next generation sequencing does, however, have disadvantages in that it has difficulty in managing screen copy number, as well as fusion genes.
